Literature DB >> 22547611

Brentuximab vedotin and panobinostat: new drugs for Hodgkin's lymphoma--can they make one of medical oncology's chemotherapy success stories more successful?

George P Canellos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547611     DOI： 10.1200/JCO.2011.39.6416

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.

Authors:  Carmelo Carlo-Stella; Francesca Ricci; Serena Dalto; Rita Mazza; Michele Malagola; Francesca Patriarca; Simonetta Viviani; Domenico Russo; Laura Giordano; Luca Castagna; Paolo Corradini; Armando Santoro
Journal:  Oncologist       Date:  2015-02-10

2.  The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.

Authors:  S L Locatelli; G Careddu; G Inghirami; L Castagna; P Sportelli; A Santoro; C Carlo-Stella
Journal:  Leukemia       Date:  2016-08-08       Impact factor: 11.528

Review 3.  Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma.

Authors:  Huimin Ma; Xin Li; Meng Lin; Kebing Lv; Mingzhi Zhang; Xiaolong Wu
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

4.  A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin.

Authors:  Zhi-Gang Cao; Hong-Wei Zhou; Chao-Jin Peng; Mo Liu; Yu Du; Qing-Ming Yang
Journal:  Chin J Cancer       Date:  2013-04-01

5.  Nucleic Acid Aptamers as Potential Therapeutic and Diagnostic Agents for Lymphoma.

Authors:  Ka-To Shum; Jiehua Zhou; John J Rossi
Journal:  J Cancer Ther       Date:  2013-06-01

Review 6.  Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.

Authors:  Luca Castagna; Carmelo Carlo-Stella; Rita Mazza; Armando Santoro
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-02-15       Impact factor: 2.576
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.